130 related articles for article (PubMed ID: 8738624)
1. Etoposide, epirubicin and carboplatin in hormone-refractory prostate cancer.
Fuse H; Muraishi Y; Fujishiro Y; Katayama T
Int Urol Nephrol; 1996; 28(1):79-85. PubMed ID: 8738624
[TBL] [Abstract][Full Text] [Related]
2. Bi-weekly epirubicin, etoposide and low-dose dexamethasone for hormone-refractory prostate cancer.
Odrazka K; Vaculikova M; Petera J; Moravek P; Prosvic P; Zoul Z; Rydel L; Brodak M; Veselsky Z; Louda M; Simakova E
Int J Urol; 2003 Jul; 10(7):387-91. PubMed ID: 12823694
[TBL] [Abstract][Full Text] [Related]
3. Use of high-dose etoposide/ifosfamide/carboplatin/epirubicin and peripheral blood progenitor cell transplantation in limited-disease small cell lung cancer.
Brugger W; Frommhold H; Pressler K; Mertelsmann R; Kanz L
Semin Oncol; 1995 Feb; 22(1 Suppl 2):3-8. PubMed ID: 7531368
[TBL] [Abstract][Full Text] [Related]
4. Epirubicin carboplatin and 5-fluorouracil (ECarboF) chemotherapy in metastatic hormone refractory prostate cancer.
Birtle AJ; Newby JC; Harland SJ
Br J Cancer; 2004 Oct; 91(8):1472-6. PubMed ID: 15381936
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of paclitaxel, estramustine, etoposide, and carboplatin in the treatment of patients with hormone-refractory prostate carcinoma.
Smith DC; Chay CH; Dunn RL; Fardig J; Esper P; Olson K; Pienta KJ
Cancer; 2003 Jul; 98(2):269-76. PubMed ID: 12872344
[TBL] [Abstract][Full Text] [Related]
6. Is it reasonable to consider second-line chemotherapy in patients with hormone-refractory prostate cancer?
Odrazka K; Vaculikova M; Dolezel M; Petera J; Moravek P; Prosvic P; Zoul Z; Vosmik M; Dolezal J; Simakova E
Oncol Rep; 2005 Oct; 14(4):1077-81. PubMed ID: 16142375
[TBL] [Abstract][Full Text] [Related]
7. A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: Cancer and Leukemia Group B 99813.
Oh WK; Halabi S; Kelly WK; Werner C; Godley PA; Vogelzang NJ; Small EJ;
Cancer; 2003 Dec; 98(12):2592-8. PubMed ID: 14669278
[TBL] [Abstract][Full Text] [Related]
8. Weekly alternating non-cross-resistant chemotherapy for small cell lung cancer with a good prognosis: a study of the Hellenic Cooperative Oncology Group.
Skarlos DV; Samantas E; Pectasides D; Pavlidis N; Kalofonos C; Klouvas G; Panoussaki E; Tsiakopoulos E; Poulakis N; Fountzilas G
Am J Clin Oncol; 1999 Feb; 22(1):87-93. PubMed ID: 10025390
[TBL] [Abstract][Full Text] [Related]
9. Alternated approach with local irradiation and combination chemotherapy including cisplatin or carboplatin plus epirubicin and etoposide in intermediate stage non-small cell lung cancer.
Comella P; Scoppa G; Daponte A; Musetta G; Anania C; Maiorino A; Curcio C; Casaretti R; Comella G
Cancer; 1994 Oct; 74(7):1874-81. PubMed ID: 8082093
[TBL] [Abstract][Full Text] [Related]
10. Paclitaxel, estramustine, and etoposide in the treatment of hormone-refractory prostate cancer.
Pienta KJ; Smith DC
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-72-S15-77. PubMed ID: 9346227
[TBL] [Abstract][Full Text] [Related]
11. A phase I study of prolonged ambulatory infusion carboplatin with oral etoposide showing activity in prostate cancer.
Olver IN; Stephenson J; Schulze D
Cancer Chemother Pharmacol; 2000; 46(4):338-41. PubMed ID: 11052632
[TBL] [Abstract][Full Text] [Related]
12. Treatment of relapse of small cell lung cancer in selected patients with the initial combination chemotherapy carboplatin, etoposide, and epirubicin.
Collard P; Weynants P; Francis C; Rodenstein DO
Thorax; 1992 May; 47(5):369-71. PubMed ID: 1319088
[TBL] [Abstract][Full Text] [Related]
13. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
[TBL] [Abstract][Full Text] [Related]
14. Phase I study of chemotherapy with carboplatin, epirubicin, and escalating dose of VP-16 with G-CSF support in extensive small cell lung cancer.
Gridelli C; D'Aprile M; Palmeri S; Curcio C; Rossi A; Gebbia V; Veltri E; Pepe R; Pistillucci G; Bianco AR
Am J Clin Oncol; 1996 Dec; 19(6):589-91. PubMed ID: 8931678
[TBL] [Abstract][Full Text] [Related]
15. High-dose treatment with carboplatin, etoposide, and ifosfamide followed by autologous stem-cell transplantation in relapsed or refractory germ cell cancer: a phase I/II study. The German Testicular Cancer Cooperative Study Group.
Siegert W; Beyer J; Strohscheer I; Baurmann H; Oettle H; Zingsem J; Zimmermann R; Bokemeyer C; Schmoll HJ; Huhn D
J Clin Oncol; 1994 Jun; 12(6):1223-31. PubMed ID: 7911158
[TBL] [Abstract][Full Text] [Related]
16. Tandem high-dose therapy with ifosfamide, epirubicin, carboplatin and peripheral blood stem cell support is an effective adjuvant treatment for high-risk primary breast cancer.
Haas R; Schmid H; Hahn U; Hohaus S; Goldschmidt H; Murea S; Kaufmann M; Wannenmacher M; Wallwiener D; Bastert G; Hunstein W
Eur J Cancer; 1997 Mar; 33(3):372-8. PubMed ID: 9155519
[TBL] [Abstract][Full Text] [Related]
17. Combination of epirubicin and cisplatin in hormone-refractory metastatic prostate cancer.
Huan SD; Stewart DJ; Aitken SE; Segal R; Yau JC
Am J Clin Oncol; 1999 Oct; 22(5):471-4. PubMed ID: 10521061
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of oral estramustine, oral etoposide, and intravenous paclitaxel in hormone-refractory prostate cancer.
Smith DC; Esper P; Strawderman M; Redman B; Pienta KJ
J Clin Oncol; 1999 Jun; 17(6):1664-71. PubMed ID: 10561202
[TBL] [Abstract][Full Text] [Related]
19. Suramin in combination with weekly epirubicin for patients with advanced hormone-refractory prostate carcinoma.
Falcone A; Antonuzzo A; Danesi R; Allegrini G; Monica L; Pfanner E; Masi G; Ricci S; Del Tacca M; Conte P
Cancer; 1999 Aug; 86(3):470-6. PubMed ID: 10430255
[TBL] [Abstract][Full Text] [Related]
20. [CBDCA, etoposide and epirubicin high-dose combination chemotherapy supported by peripheral blood stem cell transplantation (PBSCT) in metastatic breast cancer].
Suwata J; Takada S; Murata N; Ishizuka N; Idezuki Y; Kobayashi M
Gan To Kagaku Ryoho; 1999 Jan; 26(1):83-8. PubMed ID: 9987502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
